Literature DB >> 16806625

Serum creatine kinase levels in chronic psychosis patients--a comparison between atypical and conventional antipsychotics.

Kristina Melkersson1.   

Abstract

Creatine kinase is an important enzyme in the energy metabolism of many cell types, including muscle cells. Increased serum levels of creatine kinase may serve as a marker of enhanced creatine kinase synthesis in muscle cells or muscle cell membrane damage. The purpose of this study was to compare serum creatine kinase levels in chronic psychosis patients treated with either atypical or conventional antipsychotics. Forty-nine patients, receiving clozapine (n=18), or olanzapine (n=18), or conventional agents (n=13), were studied. Fasting serum samples were analyzed for creatine kinase. A significant difference in median creatine kinase level was found among the treatment groups (p=0.03), in that the creatine kinase level was higher both in the patients receiving clozapine and in the patients receiving olanzapine, compared to that in patients receiving conventional antipsychotics, p=0.001 and p<0.0001, respectively. In addition, elevated creatine kinase levels above the upper limit of normal were found in 6 (17%) of the patients treated with clozapine or olanzapine, but in none of the patients treated with conventional agents. In summary, the present results indicate that therapy with atypical antipsychotics like clozapine and olanzapine, in contrast to conventional agents, may be associated with serum creatine kinase elevation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16806625     DOI: 10.1016/j.pnpbp.2006.04.025

Source DB:  PubMed          Journal:  Prog Neuropsychopharmacol Biol Psychiatry        ISSN: 0278-5846            Impact factor:   5.067


  9 in total

1.  Case report of olanzapine-associated elevation of serum creatine kinase in a 16-year-old boy with heat stroke.

Authors:  Mohammad Jafferany; Jennifer Lowry
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2008

Review 2.  Brexpiprazole: so far so good.

Authors:  Saibal Das; Preeti Barnwal; Blessed Winston A; Somnath Mondal; Indranil Saha
Journal:  Ther Adv Psychopharmacol       Date:  2016-02

3.  Acute rhabdomyolysis during treatment with amisulpride and metformin.

Authors:  Francesco Ursini; Elena Succurro; Alessandro Grembiale; Franco Arturi
Journal:  Eur J Clin Pharmacol       Date:  2009-12-18       Impact factor: 2.953

Review 4.  Creatine metabolism and psychiatric disorders: Does creatine supplementation have therapeutic value?

Authors:  Patricia J Allen
Journal:  Neurosci Biobehav Rev       Date:  2012-03-24       Impact factor: 8.989

5.  Abnormal laboratory values during the acute and recovery phases in schizophrenic patients: a retrospective study.

Authors:  Takahiko Nagamine
Journal:  Neuropsychiatr Dis Treat       Date:  2010-06-24       Impact factor: 2.570

6.  A snapshot of plasma metabolites in first-episode schizophrenia: a capillary electrophoresis time-of-flight mass spectrometry study.

Authors:  S Koike; M Bundo; K Iwamoto; M Suga; H Kuwabara; Y Ohashi; K Shinoda; Y Takano; N Iwashiro; Y Satomura; T Nagai; T Natsubori; M Tada; H Yamasue; K Kasai
Journal:  Transl Psychiatry       Date:  2014-04-08       Impact factor: 6.222

7.  Exceptionally high creatine kinase levels in risperidone-induced neuroleptic malignant syndrome: A case report.

Authors:  Siddiqa Ozaal; Gaya Katulanda
Journal:  SAGE Open Med Case Rep       Date:  2022-03-15

8.  Case report: One child with an autism spectrum disorder who had chronically elevated serum levels of CK and CK-MB.

Authors:  Ping Rong; Shuyi Zhao; Qianfang Fu; Mengrui Chen; Libin Yang; Yifei Song; Xilian Zhang; Rong Ma
Journal:  Front Psychiatry       Date:  2022-09-06       Impact factor: 5.435

9.  Repeated use of SSRIs potentially associated with an increase on serum CK and CK-MB in patients with major depressive disorder: a retrospective study.

Authors:  Shengwei Wu; Yufang Zhou; Zhengzheng Xuan; Linghui Xiong; Xinyu Ge; Junrong Ye; Yun Liu; Lexin Yuan; Yan Xu; Guoan Ding; Aixiang Xiao; Jianxiong Guo; Lin Yu
Journal:  Sci Rep       Date:  2021-06-28       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.